Creative Medical Technology Holdings, Inc.

NasdaqCM:CELZ Stock Report

Market Cap: US$4.5m

Creative Medical Technology Holdings Valuation

Is CELZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CELZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CELZ?

Key metric: As CELZ barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CELZ. This is calculated by dividing CELZ's market cap by their current book value.
What is CELZ's PB Ratio?
PB Ratio0.7x
BookUS$6.56m
Market CapUS$4.46m

Price to Book Ratio vs Peers

How does CELZ's PB Ratio compare to its peers?

The above table shows the PB ratio for CELZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.8x
ONCT Oncternal Therapeutics
0.4x-29.5%US$3.4m
ONVO Organovo Holdings
1.7x-10.7%US$5.4m
BCDA BioCardia
2.9x-13.5%US$7.5m
OGEN Oragenics
2.3xn/aUS$3.3m
CELZ Creative Medical Technology Holdings
0.7x72.7%US$4.5m

Price-To-Book vs Peers: CELZ is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1.8x).


Price to Book Ratio vs Industry

How does CELZ's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
CELZ 0.7xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CELZ is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is CELZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CELZ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CELZ's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies